H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Anixa Biosciences to $7 from $12 and keeps a Buy rating on the shares following the fiscal Q2 report. The analyst believes the company may have an operational runway of over two years.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIX:
Questions or Comments about the article? Write to editor@tipranks.com